Renal
Records checked
Compiled and citation-checked by GLP-1 Receptor Agonists editorial desk
Qualified clinical review None on record
Records whose assigned subject headings cover kidney function, filtration rate, albuminuria or renal disease states. 10 of the 186 records indexed across this publication's scope carry at least one of them, covering 7 of the 17 compounds.
Assignment is mechanical. A record sits under this endpoint because the indexer attached one of the subject headings listed further down, not because anyone read it. The cell counts records. It does not report a result, a direction or a magnitude, and nothing in the corpus would let it.
Record coverage by compound and record class
| Compound | Ph 3 | Ph 2 | Ph 1 | Trial, no phase | Review | Other | All |
|---|---|---|---|---|---|---|---|
| Amylin | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cagrilintide | 0 | 0 | 0 | 0 | 0 | 1 [2] | 1 |
| Dulaglutide | 0 | 0 | 0 | 1 [6] | 0 | 0 | 1 |
| Eloralintide | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exenatide | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GLP-1 | 0 | 0 | 0 | 0 | 1 [7] | 0 | 1 |
| Liraglutide | 0 | 0 | 0 | 1 [10] | 0 | 0 | 1 |
| Lixisenatide | 0 | 0 | 0 | 0 | 0 | 2 [8, 9] | 2 |
| Maridebart cafraglutide | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mazdutide | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Orforglipron | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Petrelintide | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pramlintide | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retatrutide | 0 | 0 | 0 | 1 [1] | 0 | 1 [3] | 2 |
| Semaglutide | 0 | 0 | 0 | 2 [4, 5] | 0 | 0 | 2 |
| Survodutide | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tirzepatide | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Column keys: Ph 3 phase 3; Ph 2 phase 2; Ph 1 phase 1; Trial, no phase trial, no phase assigned; Review review or synthesis; Other not a registered trial record. Phase is read from the publication type the indexer assigned to each record, never from its title.
A zero cell records that no indexed record for that compound carries one of these subject headings. It is the absence of a retrieved report, never the absence of the thing itself. The full record set for each compound is held on its own trial page.
Subject headings that place a record here
The full set is fixed and printed here so the assignment can be checked by hand against the method. 10 of the 10 headings in the set occur on at least one record in scope.
| Subject heading | Records |
|---|---|
| Diabetic Nephropathies | 6 |
| Glomerular Filtration Rate | 6 |
| Albuminuria | 3 |
| Creatinine | 2 |
| Kidney | 2 |
| Kidney Diseases | 1 |
| Kidney Failure, Chronic | 1 |
| Kidney Function Tests | 1 |
| Renal Insufficiency | 1 |
| Renal Insufficiency, Chronic | 1 |
The records
10 distinct records, newest first within each class. A record indexed under more than one compound is listed once and named under each.
Trial, no phase assigned — 5 records
| No. | Identifier | Year | Record | Model | Indexed under | Subject headings |
|---|---|---|---|---|---|---|
| 1 | pmid:41160422 | 2026 | Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · Clinical Trial Protocol, research-article | other | Retatrutide | Humans; Diabetes Mellitus, Type 2; Obesity; Fatty Acids; Peptides; Hypoglycemic Agents; Kidney Function Tests; Glomerular Filtration Rate |
| 4 | pmid:40162642 | 2025 | Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes The New England journal of medicine · Equivalence Trial, Multicenter Study | human trial | Semaglutide | Humans; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Administration, Oral; Follow-Up Studies; Double-Blind Method; Aged; Middle Aged |
| 5 | pmid:38785209 | 2024 | Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes The New England journal of medicine · Multicenter Study, Randomized Controlled Trial | human trial | Semaglutide | Humans; Diabetic Nephropathies; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Glomerular Filtration Rate; Injections, Subcutaneous; Double-Blind Method |
| 6 | pmid:31189509 | 2019 | Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial Lancet (London, England) · Multicenter Study, Randomized Controlled Trial | human trial | Dulaglutide | Humans; Diabetic Nephropathies; Albuminuria; Diabetes Mellitus, Type 2; Creatinine; Recombinant Fusion Proteins; Hypoglycemic Agents; Glomerular Filtration Rate |
| 10 | pmid:28854085 | 2017 | Liraglutide and Renal Outcomes in Type 2 Diabetes The New England journal of medicine · Comparative Study, Randomized Controlled Trial | human trial | Liraglutide | Humans; Diabetic Nephropathies; Kidney Failure, Chronic; Albuminuria; Diabetes Mellitus, Type 2; Creatinine; Hypoglycemic Agents; Glomerular Filtration Rate |
Review or synthesis — 1 record
| No. | Identifier | Year | Record | Model | Indexed under | Subject headings |
|---|---|---|---|---|---|---|
| 7 | pmid:31422062 | 2019 | Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials The lancet. Diabetes & endocrinology · Meta-Analysis, Research Support, Non-U.S. Gov't | other | GLP-1 | Humans; Diabetic Nephropathies; Diabetic Angiopathies; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Treatment Outcome; Randomized Controlled Trials as Topic; Glucagon-Like Peptide-1 Receptor Agonists |
Not a registered trial record — 4 records
| No. | Identifier | Year | Record | Model | Indexed under | Subject headings |
|---|---|---|---|---|---|---|
| 2 | pmid:42228334 | 2026 | Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide Clinical pharmacokinetics · research-article, Multicenter Study | human trial | Cagrilintide | Humans; Liver Diseases; Hypoglycemic Agents; Injections, Subcutaneous; Area Under Curve; Adult; Aged; Middle Aged |
| 3 | pmid:39212900 | 2025 | Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice Endocrine · Comparative Study | rodent | Retatrutide | Kidney; Animals; Mice, Inbred C57BL; Mice; Diabetic Nephropathies; Diabetes Mellitus, Experimental; Blood Glucose; Fatty Acids |
| 8 | pmid:30292589 | 2018 | Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial The lancet. Diabetes & endocrinology · Research Support, Non-U.S. Gov't | other | Lixisenatide | Humans; Kidney Diseases; Albuminuria; Diabetes Mellitus, Type 2; Peptides; Glomerular Filtration Rate; Treatment Outcome; Middle Aged |
| 9 | pmid:28449402 | 2017 | Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial Diabetes, obesity & metabolism · Comparative Study, Research Support, Non-U.S. Gov't | human trial | Lixisenatide | Kidney; Humans; Diabetic Nephropathies; Diabetes Mellitus, Type 2; Insulin; Peptides; Hypoglycemic Agents; Glomerular Filtration Rate |
What this page does not say
- It does not say what any record found. Subject headings describe what a record is about, not what it concluded.
- It does not rank the compounds. The column order is fixed by record class and the row order is alphabetical, neither of which carries a judgement.
- It does not represent the literature. The counts are of records this corpus carries; the queries behind them returned 48,938 records in total across the compounds in scope.
- It is not clinical guidance, and it is not reviewed by a clinician. The disclaimer states the limits in full.